Na Febụwarị 9, 2026, ebe nrụọrụ weebụ gọọmentị nke Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) kwupụtara na a na-eme atụmatụ inye ZL-1310 maka ịgba ọgwụ, nke bụ DLL3-targeting antibody-drug conjugate (ADC), aha ọgwụgwọ Breakthrough.
Dịka onye otu Peking University Cancer Hospital Medical Consortium na ụlọ ọgwụ pụrụ iche nke oge a na Beijing nke abụọ, Beijing South Region Oncology Hospital International Department na-eji usoro nchọpụta na ọgwụgwọ siri ike nke ọtụtụ ngalaba iji tinye ọgwụgwọ ndị a na-eduga n'ụwa niile ngwa ngwa na atụmatụ ọgwụgwọ nke ndị ọrịa mba ụwa. Ọ bụrụ na gị ma ọ bụ onye ị hụrụ n'anya na-eche ihe ịma aka nke ọgwụgwọ nke abụọ ma ọ bụ nke ikpeazụ maka ọrịa kansa akpa ume obere ihu, biko gụọ data dị n'okpuru ma kpọtụrụ anyị ozugbo.
Kpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region ugbu a:
- Ekwentị: 400-880-3716
- WeChat ID: 17801183037
- Email ①: 100085_010@163.com
- Email ②: myimmnet@163.com
**Data siri ike: Ruo 86% irè n'ahụ ndị ọrịa nwere nsogbu ụbụrụ**
Na Nzukọ Kwa Afọ nke American Society of Clinical Oncology (ASCO) nke afọ 2025, e gosipụtara data ọmụmụ ihe gbasara ahụike nke usoro 1a/1b zuru ụwa ọnụ maka ZL-1310.
Maka ndị ọrịa a gwọrọla n'oge gara aga (ọgwụgwọ nke abụọ):
- Ọnụọgụ nzaghachi ebumnuche (uORR) a na-anaghị ekwenye ekwenye ruru 67%, yana ọnụego njikwa ọrịa (DCR) nke 97%.
- N'ime otu ọgwụ bayọlọji kacha mma (1.6 mg/kg): Ọnụọgụ nzaghachi ebumnuche (ORR) rịrị elu ruo 79%, yana ọnụego njikwa ọrịa (DCR) nke 100%.
- Nke a pụtara: Ihe fọrọ nke nta ka ọ bụrụ ndị ọrịa iri niile natara ọgwụ a nwetara njikwa etuto ahụ, ihe fọrọ nke nta ka ọ bụrụ ndị ọrịa asatọ nwetara mbelata dị ukwuu na etuto ahụ.
Maka ndị ọrịa kacha sie ike nwere metastases ụbụrụ:
- Ndị ọrịa nwere nsogbu ụbụrụ mbụ: Ọnụego nzaghachi ebumnuche (ORR) bụ 68%.
- Ndị ọrịa na-enwetabeghị ọgwụgwọ redio n'ahụ: Ọnụọgụ nzaghachi ebumnuche (ORR) ruru 86%!
Data a dị oke mkpa. Ọgwụ chemotherapy ọdịnala na-agba mbọ ịbanye n'ime ihe mgbochi ọbara na ụbụrụ, mana ZL-1310 na-egosi ọrụ siri ike nke mgbochi etuto ahụ n'ime ụbụrụ. Maka ndị ọrịa mba ụwa na-enwe nchegbu banyere mmetụta ọjọọ nke ọgwụgwọ redio nke ụbụrụ dum, nke a na-egosi olileanya dị ukwuu nke "izere radieshon ụbụrụ."
**Nkọwa Nchekwa:** N'ime otu dose <2.0 mg/kg, ihe omume ọjọọ metụtara ọgwụgwọ (TRAEs) nke ọkwa 3 ma ọ bụ karịa bụ naanị 6%, enweghị akụkọ ọ bụla gbasara ọrịa akpa ume interstitial (ILD) ma ọ bụ ihe omume ịkwụsị ọgwụgwọ metụtara ọgwụgwọ.
—
**III. Gịnị mere ị ga-eji họrọ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Mpaghara Ndịda Beijing?**
Maka ndị ọrịa mba ụwa, ịnweta ọgwụgwọ ọhụrụ abụghị naanị gbasara "ma ọgwụ ahụ ọ dị," kamakwa usoro nhazi nke gụnyere "onye nwere ike iji ya, otu esi eji ya, na onye na-achịkwa mmetụta ndị na-adịghị mma."
Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region na-enye nyocha na njikwa zuru oke maka ọgwụgwọ kachasị ọhụrụ dịka ZL-1310 maka ndị ọrịa ruru eru. Ma ị si Ndịda Ọwụwa Anyanwụ Eshia, Middle East, Europe, ma ọ bụ America, anyị nwere usoro ọrụ ahụike mba ụwa nke e guzobere nke ọma.
Anyị na-enye ọrụ zuru oke site na ndụmọdụ tupu ụlọ ọgwụ, ntụgharị asụsụ dị iche iche, akwụkwọ visa ahụike, ruo na nleba anya n'ịgwọ ọrịa. Nrubeisi siri ike na iwu "otu dọkịta, otu onye ọrịa, otu ọnụ ụlọ" na-eme ka a na-asọpụrụ nzuzo na ùgwù gị nke ọma, ọbụlagodi na mba ọzọ.
Ugbu a, US FDA enyela ZL-1310 ikike maka aha ọgwụ Orphan na aha ngwa ngwa site n'aka ụlọ ọrụ FDA. Atụmatụ itinye ya na nhazi ọgwụgwọ Breakthrough nke China ga-eme ka ọ dị ngwa ngwa na China.
Ekwela ka ihe mgbochi asụsụ, oghere ozi, ma ọ bụ usoro siri ike gbochie gị ịnweta ọgwụgwọ dị elu. Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region eguzobela ụzọ ndụ maka ndị ọrịa mba ụwa.
Were ekwentị ma ọ bụ kpọtụrụ anyị site na WeChat ma ọ bụ email iji kọọrọ gị ọnọdụ gị. Ndị ọkachamara ahụike anyị ga-enye nyocha mbụ n'ime awa iri abụọ na anọ.
- Ekwentị (nzukọ awa 24): 400-880-3716
- WeChat (nkwukọrịta ozugbo): 17801183037 (na-akwado Bekee na Chaịna)
- Email (maka ndekọ ahụike):
- 100085_010@163.com
- myimmnet@163.com
Oge ozi: Febụwarị-12-2026